EP 1527068 A2 20050504 - NOVEL ARYLIMIDAZOLE DERIVATIVES, THEIR USE AS NO-SYNTASE INHIBITORS AND AS MODULATORS OF SODIUM CHANNELS

Title (en)

NOVEL ARYLIMIDAZOLE DERIVATIVES, THEIR USE AS NO-SYNTASE INHIBITORS AND AS MODULATORS OF SODIUM CHANNELS

Title (de)

ARYLIMIDAZOLDERIVATE UND DEREN VERWENDUNG ALS NO SYNTHASE INHIBITOREN UND ALS MODULATOREN DER NA-KANÄLE

Title (fr)

DERIVES D'ARYLIMIDAZOLES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE NO SYNTHASES ET EN TANT QUE MODULATEURS DES CANAUX SODIQUES

Publication

EP 1527068 A2 20050504 (FR)

Application

EP 03755628 A 20030724

Priority

FR 0302336 W 20030724
FR 0209416 A 20020725

Abstract (en)

[origin: US2005234118A1] The invention concerns compounds of general formula (1) wherein R1 represents H, alkyl,cycloalkyl or cycloalkylalkyl and R2 represents H or alkyl; R3 represents H, alkyl or aralkyl; X represents a bond or a linear or branched alkylene radical (II); Y represents H, cycloalkyl, OR14, SR15, NR4R5 or A represents a bond or phenyl; B and B' are independently selected among alkyl, NR6R7, SR8 and carbocyclic aryl orheterocyclic aryl radicals with five or six members optionally substituted; R4 represents H, alkyl, aryl, cycloalkyl, cycloalkylalkyl, aralkyl, C(O)R9, C(O)OR9, -C(O)NHR9 or -SO2R9, or further aryl or aralkyl whereof the aromatic ring is optionally substituted and R5 represents in particular H or alkyl, or further R, and R5 form with the nitrogen atom bearing them a non-aromatic hetcrocycle of five to seven members optionally substituted; R6 represents (in particular) II or alkyl and R7 represents (in particular) II or alkyl; R8 represents an alkyl radical optionally substituted; R9 represents alkyl, haloakyl, cycloalkyl or cycloalkylalkyl, or further one of the aralkyl or aryl or heteroaryl radicals optionally substituted; R14 and R15 independently represent (in particular) alkyl, phenyl or aralkyl. The compounds of general formula (I) can be used as NO synthase inhibitors and as modulators of sodium channels (for treating pains, multiple sclerosis, the central nervous system or the peripheral nervous system and the like).

IPC 1-7

C07D 409/12; A61K 31/417; A61P 25/00; C07D 409/14

IPC 8 full level

C07D 233/64 (2006.01); A61K 31/4164 (2006.01); A61K 31/4178 (2006.01); A61P 1/04 (2006.01); A61P 1/14 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01); A61P 9/00 (2006.01); A61P 9/06 (2006.01); A61P 9/10 (2006.01); A61P 11/00 (2006.01); A61P 11/02 (2006.01); A61P 11/06 (2006.01); A61P 15/00 (2006.01); A61P 15/10 (2006.01); A61P 15/12 (2006.01); A61P 17/02 (2006.01); A61P 17/06 (2006.01); A61P 19/02 (2006.01); A61P 21/00 (2006.01); A61P 25/00 (2006.01); A61P 25/02 (2006.01); A61P 25/04 (2006.01); A61P 25/06 (2006.01); A61P 25/08 (2006.01); A61P 25/14 (2006.01); A61P 25/16 (2006.01); A61P 25/18 (2006.01); A61P 25/20 (2006.01); A61P 25/22 (2006.01); A61P 25/24 (2006.01); A61P 25/28 (2006.01); A61P 25/32 (2006.01); A61P 25/36 (2006.01); A61P 27/02 (2006.01); A61P 27/16 (2006.01); A61P 29/00 (2006.01); A61P 29/02 (2006.01); A61P 31/12 (2006.01); A61P 31/18 (2006.01); A61P 31/22 (2006.01); A61P 33/00 (2006.01); A61P 35/00 (2006.01); A61P 37/06 (2006.01); A61P 37/08 (2006.01); A61P 39/02 (2006.01); A61P 43/00 (2006.01); C07D 409/12 (2006.01); C07D 409/14 (2006.01)

CPC (source: EP US)

A61P 1/04 (2018.01 - EP); A61P 1/14 (2018.01 - EP); A61P 3/04 (2018.01 - EP); A61P 3/10 (2018.01 - EP); A61P 9/00 (2018.01 - EP); A61P 9/06 (2018.01 - EP); A61P 9/10 (2018.01 - EP); A61P 11/00 (2018.01 - EP); A61P 11/02 (2018.01 - EP); A61P 11/06 (2018.01 - EP); A61P 15/00 (2018.01 - EP); A61P 15/10 (2018.01 - EP); A61P 15/12 (2018.01 - EP); A61P 17/00 (2018.01 - EP); A61P 17/02 (2018.01 - EP); A61P 17/06 (2018.01 - EP); A61P 19/02 (2018.01 - EP); A61P 21/00 (2018.01 - EP); A61P 25/00 (2018.01 - EP); A61P 25/02 (2018.01 - EP); A61P 25/04 (2018.01 - EP); A61P 25/06 (2018.01 - EP); A61P 25/08 (2018.01 - EP); A61P 25/14 (2018.01 - EP); A61P 25/16 (2018.01 - EP); A61P 25/18 (2018.01 - EP); A61P 25/20 (2018.01 - EP); A61P 25/22 (2018.01 - EP); A61P 25/24 (2018.01 - EP); A61P 25/28 (2018.01 - EP); A61P 25/32 (2018.01 - EP); A61P 25/36 (2018.01 - EP); A61P 27/02 (2018.01 - EP); A61P 27/16 (2018.01 - EP); A61P 29/00 (2018.01 - EP); A61P 29/02 (2018.01 - EP); A61P 31/12 (2018.01 - EP); A61P 31/18 (2018.01 - EP); A61P 31/22 (2018.01 - EP); A61P 33/00 (2018.01 - EP); A61P 35/00 (2018.01 - EP); A61P 37/06 (2018.01 - EP); A61P 37/08 (2018.01 - EP); A61P 39/02 (2018.01 - EP); A61P 43/00 (2018.01 - EP); C07D 409/12 (2013.01 - EP US); C07D 409/14 (2013.01 - EP US)

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DOCDB simple family (publication)

US 2005234118 A1 20051020; US 7192975 B2 20070320; AR 040701 A1 20050413; AT E383354 T1 20080115; AU 2003273468 A1 20040216; AU 2003273468 B2 20081218; BR 0312289 A 20050412; CA 2493751 A1 20040205; CN 100340556 C 20071003; CN 1671701 A 20050921; DE 60318584 D1 20080221; DE 60318584 T2 20090108; EP 1527068 A2 20050504; EP 1527068 B1 20080109; ES 2299719 T3 20080601; FR 2842808 A1 20040130; FR 2842808 B1 20040910; HR P20041232 A2 20050228; IL 165612 A0 20060115; JP 2005533857 A 20051110; MX PA05000931 A 20050323; NZ 537047 A 20050826; PL 374858 A1 20051114; RU 2005105058 A 20050720; RU 2323216 C2 20080427; WO 2004011402 A2 20040205; WO 2004011402 A3 20040429

DOCDB simple family (application)

US 51726704 A 20041206; AR P030102689 A 20030725; AT 03755628 T 20030724; AU 2003273468 A 20030724; BR 0312289 A 20030724; CA 2493751 A 20030724; CN 03817821 A 20030724; DE 60318584 T 20030724; EP 03755628 A 20030724; ES 03755628 T 20030724; FR 0209416 A 20020725; FR 0302336 W 20030724; HR P20041232 A 20041230; IL 16561204 A 20041207; JP 2004523872 A 20030724; MX PA05000931 A 20030724; NZ 53704703 A 20030724; PL 37485803 A 20030724; RU 2005105058 A 20030724